In Section C, individuals will get ABBV-744 and oral navitoclax. In Section D, individuals will receive ABBV-744 and ruxolitinib. Participants will receive treatment right until illness progression or even the participants are unable to tolerate the study drugs. - Participant consumed grapefruit or grapefruit merchandise within three times before the https://abbv-744-brd4-inhibitor-m98013.livebloggs.com/38366674/5-tips-about-clinical-effectiveness-of-abbv-744-in-aml-patients-you-can-use-today